Effects of heteropolyanions and nucleoside analogues on rabies virus: In vitro study of syntheses and viral production

Bussereau, F; Ermine, Alain

doi:10.1016/s0769-2617(83)80022-7

Cited by 17 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro studies have demonstrated its efficacy [151], but this has not been seen in in vivo studies, owing to its limited capacity to cross the BBB [152]. Intrathecal or intraventricular administration with Ommaya reservoir might be of benefit, but a trial in a single human rabies case, using the intrathecal and intravenous routes, failed, in combination with IFN-α [153].…”

Section: Immunizationmentioning

confidence: 99%

Perspectives in Diagnosis and Treatment of Rabies Viral Encephalitis: Insights from Pathogenesis

et al. 2016

View full text Add to dashboard Cite

Rabies viral encephalitis, though one of the oldest recognized infectious disease of humans, remains an incurable, fatal encephalomyelitis, despite advances in understanding of its pathobiology. Advances in science have led us on the trail of the virus in the host, but the sanctuaries in which the virus remains hidden for its survival are unknown. Insights into host-pathogen interactions have facilitated evolving immunologic therapeutic strategies, though we are far from a cure. Most of the present-day knowledge has evolved from in vitro studies using fixed (attenuated) laboratory strains that may not be applicable in the clinical setting. Much remains to be unraveled about this elusive virus. This review attempts to re-examine the current advances in understanding of the pathobiology of the rabies virus that modulate the diagnosis, treatment, and prevention of this fatal disease.

show abstract

Section: Immunizationmentioning

confidence: 99%

Perspectives in Diagnosis and Treatment of Rabies Viral Encephalitis: Insights from Pathogenesis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Ribavirin also has immunomodulatory properties that may, in part, account for its antiviral properties in vivo [25]. Ribavirin has in vitro activity against rabies virus infection [26,27], although efficacy was not demonstrated in a study that used animal models [28]. Ribavirin is typically administered intravenously with both loading and maintenance doses.…”

Section: Rabies Immunoglobulinmentioning

confidence: 99%

Management of Rabies in Humans

Jackson

Warrell

Rupprecht³

et al. 2003

CLIN INFECT DIS

212

116

View full text Add to dashboard Cite

Rabies is a fatal disease in humans, and, to date, the only survivors of the disease have received rabies vaccine before the onset of illness. The approach to management of the rabies normally should be palliative. In unusual circumstances, a decision may be made to use an aggressive approach to therapy for patients who present at an early stage of clinical disease. No single therapeutic agent is likely to be effective, but a combination of specific therapies could be considered, including rabies vaccine, rabies immunoglobulin, monoclonal antibodies, ribavirin, interferon-alpha, and ketamine. Corticosteroids should not be used. As research advances, new agents may become available in the future for the treatment of human rabies.

show abstract

“…Anti-RABV agents can be identified by examining compound libraries using either cellbased Chávez et al, 2006) or cell-free screening assays (Lingappa et al, 2013). Cell-based systems using native RABV infection of susceptible cell lines have provided a more robust and replicable approach to identify anti-RABV compounds Bussereau and Ermine, 1983;Chávez et al, 2006). Therefore, we employed a cell-based system using previously generated rRABV encoding Nluc (Anindita et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Ribavirin-related compounds exert in vitro inhibitory effects toward rabies virus

et al. 2018

View full text Add to dashboard Cite

Rabies remains an invariably fatal neurological disease despite the availability of a preventive vaccination and post-exposure prophylaxis that must be immediately administered to the exposed individual before symptom onset. There is no effective medication for treatment during the symptomatic phase. Ribavirin, a guanine nucleoside analog, is a potent inhibitor of rabies virus (RABV) replication in vitro but lacks clinical efficacy. Therefore, we attempted to identify potential ribavirin analogs with comparable or superior anti-RABV activity. Antiviral activity and cytotoxicity of the compounds were initially examined in human neuroblastoma cells. Among the tested compounds, two exhibited a 5- to 27-fold higher anti-RABV activity than ribavirin. Examination of the anti-RABV mechanisms of action of the compounds using time-of-addition and minigenome assays revealed that they inhibited viral genome replication and transcription. Addition of exogenous guanosine to RABV-infected cells diminished the antiviral activity of the compounds, suggesting that they are involved in guanosine triphosphate (GTP) pool depletion by inhibiting inosine monophosphate dehydrogenase (IMPDH). Taken together, our findings underline the potency of nucleoside analogs as a class of antiviral compounds for the development of novel agents against RABV.

show abstract

Effects of heteropolyanions and nucleoside analogues on rabies virus: In vitro study of syntheses and viral production

Cited by 17 publications

References 13 publications

Perspectives in Diagnosis and Treatment of Rabies Viral Encephalitis: Insights from Pathogenesis

Perspectives in Diagnosis and Treatment of Rabies Viral Encephalitis: Insights from Pathogenesis

Management of Rabies in Humans

Ribavirin-related compounds exert in vitro inhibitory effects toward rabies virus

Contact Info

Product

Resources

About